-
Mashup Score: 1👀 Spotlight on Myelofibrosis 2024: The Critical Evolution of JAK Inhibitors - UC Irvine - Angela Fleischman, MD - 2 month(s) ago
Angela Fleischman, MD – UC Irvine delves into the latest advancements in myelofibrosis treatment, particularly focusing on the role of JAK inhibitors and the emerging potential of gene therapy as of 2024. It emphasizes the critical need for specialized care in non-malignant hematology clinics and the promising future of personalized treatment strategies for myelofibrosis patients. Dr. Zahra Pakbaz’s exploration of the American Society of Hematology meeting emphasized the vital role of Non-Malignant
Source: info.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1🎓 AML ASH Updates [2024 SLIDES] - Dr. Kiran Naqvi, MD - 3 month(s) ago
Kiran Naqvi, MD – UCI presents findings on the efficacy and safety of Quizartinib, a FLIT-III inhibitor, in combination therapy for newly diagnosed and relapse refractory AML, showcasing significant improvements in overall survival, response rates, and MRD negativity, with potential implications for frontline treatment strategies. Stefan Ciurea, MD – UCI provides 2024 updated slides on CAR T-cell therapy for multiple myeloma and lymphoma, discussing efficacy, safety, predictors of adverse events, and
Source: info.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet-
Check out our latest eNewsletter. Today's focus: 2024 AML, CAR-T cell, and Multiple Myeloma Updates with SLIDES from ASH. Check it out here: https://t.co/oLsuNAY9AC https://t.co/K4ueBr9fA3
-
-
Mashup Score: 0
Dr. Milind Javle, MD discusses a phase 3 trial initiated for FGFR altered cholangiocarcinoma, addressing resistance to existing treatments with the promising Tiningotinib therapy, offering new hope for patients. Dr. Vivek Subbiah, MD discusses the durable efficacy of selprocatenib in patients with RET Fusion Plus solid tumors, highlighting its significance in GI histologies and the importance of comprehensive genomic profiling in precision medicine. The Codebreak300 study, led by Dr. Dominik Paul Modest,
Source: info.oncologytube.comCategories: General Medicine News, Onc News and JournalsTweet-
@OncologyTube eNewsletter https://t.co/naMQ8xC687 ASCO #GI24 interviews @JavleMilind Tinengotinib vs. FGFR a phase 3 trial, CodeBreaK300 Update HRQoL in mCRC sotorasib + panitumumab vs. T/T or regorafenib, and @VivekSubbiah @sarahcannondocs selprocatinib in patients with RET
-
-
Mashup Score: 0📣 Phase III Trial HIMALAYA, Managing Anemia, NATALEE, SONIA and PHERGain Trial Overviews - 9 month(s) ago
Dr. Ghassan Abu, MD Alfa presents findings from the Himalaya clinical trial, a phase 3 study at Memorial Sloan Kettering Cancer Center, investigating darvalumab and tremelumab combination for intractable hepatocellular carcinoma, highlighting improved median survival of 16.5 months versus 13.5 months. Associate Professor Prithvi Bose from MD Anderson Cancer Center discussed the management of anemia in myelofibrosis, highlighting its impact on patient prognosis. Currently, there are no approved therapies
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 OncologyTube Newsletter 📣 Phase III HIMALAYA Trial @GABOUALFA @MSKCancerCenter, Managing Anemia in Myelofibrosis Prithvi Bose @MDAndersonNews, NATALEE, SONIA and PHERGain [Slides] - Sayeh Lavasani @UCIrvineHealth See The Newsletter: https://t.co/Jc5dzKErhP https://t.co/wAGP4YSyFz
-
-
Mashup Score: 1Top Lung Cancer ASCO 2023 OncologyTube Videos: Must-Watch Insights and Breakthroughs - 9 month(s) ago
Below are a few of the most viewed interviews on lung cancer OncologyTube captured at the 2023 annual conference. Ticiana Leal, MD, from the Winship Cancer Institute of Emory University, has conducted a randomized, phase 3 study called LUNAR, investigating the efficacy of Tumor Treating Field (TTFields) therapy combined with standard of care (SOC) in patients with metastatic non-small cell lung cancer (mNSCLC) who have experienced platinum failure. Qing Zhou, MD – Guangdong Lung Cancer Institute Preliminary
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 OncologyTube eNewsletter - 📣 Phase 3 LUNAR - Ticiana Leal, MD @WinshipAtEmory Saved by the Scan PSA -@atulya_khosla @BaptistHealthSF, Next-Gen RET @IASLC https://t.co/ei5SRs9yOK https://t.co/LCXuq02mZB
-
-
Mashup Score: 2📣 BCA101, DEPEND, & ASP-1929 in Combination with anti-PD-1 - 9 month(s) ago
Emrullah Yilmaz, MD Unveils the Potential of BCA101 In this exclusive interview, renowned oncologist Dr. Emrullah Yilmaz, MD, PhD, explores the promising potential of BCA101 in the treatment of Squamous Cell Cancer. Dr. Yilmaz unpacks the innovative science behind this groundbreaking therapeutic candidate, discusses its ong oing clinical trials, and more Ari Rosenberg, MD discusses the DEPEND trial which evaluates neoadjuvant nivolumab-based chemoimmunotherapy and response-stratified chemoradiation in
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 OncologyTube eNewsletter - 📣 BCA101, DEPEND, & ASP-1929 in Combination with anti-PD-1 https://t.co/e40OaW4yKf @YilmazMDPhD @CleClinicMD @AriRosenbergMD @UChicago @OncoAlert Anne Gillenwater, @MDAndersonNews https://t.co/z1EADjZJoC
-
-
Mashup Score: 1📣 Phase III KEYNOTE-716 Melanoma from ASCO 2023 - 9 month(s) ago
Jason Luke, MD, FACP from UPMC presents the final analysis of the phase 3 KEYNOTE-716 study, comparing pembrolizumab and placebo as adjuvant therapy in stage IIB or IIC melanoma. Discover the significant improvements in distant metastasis-free survival and the potential impact of pembrolizumab on overall survival. Omid Hamid, MD – The Angeles Clinic Promising Phase 1/2 Study of Combination Therapy Targeting PD-1, LAG-3, and TIM-3 Checkpoint Pathways in Advanced Solid Tumor Patients Shows Encouraging
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 OncologyTube eNewsletter - 📣 Phase III KEYNOTE-716 Melanoma from ASCO 2023 https://t.co/3d6xeB5UC8 @oncoalert @jasonlukemd @OmidHamidMD @AIMatMelanom https://t.co/lFeNCT2qns
-
-
Mashup Score: 2Phase 3 SUCCESSOR-2 Trial MeziKd Verses Kd ASCO 2023 - 10 month(s) ago
Below are the some of the most viewed multiple myeloma interviews OncologyTube.com captured from the 2023 annual conference. The SUCCESSOR-2 study led by Dr. Monique Hartley-Brown, MD, MMSc, at Dana-Farber Cancer Institute. This Phase 3 clinical trial compares the effectiveness of MeziKd (mezigdomide, carfilzomib, and dexamethasone) with the standard therapy for relapsed/refractory multiple myeloma (RRMM). Learn about the inclusion criteria, patient population, efficacy outcomes, safety profile, and key
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢 eNewsletter Phase 3 #multiplemyeloma SUCCESSOR-2 Trial MeziKd v. Kd @DrMHB1 @DanaFarber from #ASCO23 ➕ Phase 2 MonumenTAL-1 Results @UAMSMyeloma ➕ Insights from FAERS Analysis Shahzad Raza, MD @CleClinicMD https://t.co/7t3IRUSTlW https://t.co/bVkqV0cp6H
-
-
Mashup Score: 0Cancer News - 1 year(s) ago
Stay up-to-date with the latest advancements and insights in the field of oncology through OncologyTube.com’s informative blog. Our expert contributors offer valuable perspectives and research on cancer diagnosis, treatment, and management. Join our community and access a wealth of knowledge to help you stay informed and empowered in your cancer journey.
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us in raising awareness for treatment and cancer prevention by following OncologyTube’s blog! With informative videos and articles from leading experts in the field. #Oncologytube #CancerWarrior #TogetherAgainstCancer Click and Share the Link Below: https://t.co/ZSwYRUu8FH https://t.co/gPHFwhHT4L
-
-
Mashup Score: 0
ASCO [2022] Breast Cancer & Melanoma Video Overviews from the MOASC Spotlight on Oncology event held on August 27th, 2022.
Source: info.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
✉️eNewsletter 9-4-22: ASCO [2022] 👏Highlights in Breast Cancer & Melanoma: MOASC Spotlight on Oncology https://t.co/XnDn6XC1x0 @MOASC_Office #BreastCancer #Melanoma @UCSDHealth @UCIrvineHealth
-
See our latest eNewsletter: Spotlight on Myelofibrosis 2024: The Critical Evolution of JAK Inhibitors - Angela Fleischman, MD https://t.co/0okQcUDIfU @UCIrvineHealth @MOASC_Office #JAK @MPNlab #MPNews https://t.co/Cu0LD38rAY